Lung Cancer Master Protocol (Lung-MAP) - consortiapedia.fastercures.org

Research Areas

- Tool Development
- Clinical Trial
- Biomarker Research
- Drug
- Basic Research
- Drug
- Product Development
- Drugs

At a Glance

- Status: Active Consortium
- Year Launched: 2014
- Initiating Organization: FNIH
- Initiator Type: Government
- Rare disease
- Location: North America

Abstract

Lung-MAP (SWOG S1400) is a multi-drug, multi-sub-study, biomarker-driven squamous cell lung cancer clinical trial that uses state-of-the-art genomic profiling to match patients to sub-studies testing investigational treatments that may target the genomic alterations, or mutations, found to be driving the growth of their cancer. Instead of having to undergo multiple diagnostic tests to determine eligibility for many different studies, enrollees are tested just once according to a “master protocol” and assigned to one of multiple trial sub-studies, each testing a different drug from a different developer. That means shared information and infrastructure, better access for patients to promising drugs, better access for researchers to relevant enrollees based on their genomic profiles, and less time and money needed before investigational drugs can be tested.

Mission
The primary objective of each Lung-MAP trial sub-study is to learn whether a targeted cancer therapy that is matched to the genomic makeup of a patient’s lung cancer tumor is more effective than the current standard therapy in halting or reversing the progress of the disease and in extending the patient’s life. Researchers on each trial sub-study will also compare the tumor response rates and the frequency and severity of side effects patients experience on the targeted-therapy arm versus the standard-of-care arm.

Structure & Governance

Lung-MAP is a project of the National Clinical Trials Network, which is operated by the National Cancer Institute.

Financing

Lung-MAP is funded as a project under the National Clinical Trials Network.

Patent Engagement

Lung-MAP is a large clinical trial, or research study, testing several new treatments for patients who have advanced stage squamous cell lung cancer. In advanced stage patients, the cancer has usually spread to other organs in their body. The Lung-MAP trial is for advanced stage patients whose cancer has continued to grow, even after being treated with standard therapy.

Impact/Accomplishment

For links to news and media relating to Lung-MAP, click here
Links/Social Media Feed

Homepage http://www.lung-map.org/

Points of Contact

rcohman@focr.org

Sponsors & Partners

National Cancer Institute
National Clinical Trials Network
SWOG Cancer Research
Friends of Cancer Research
The Foundation for the National Institutes of Health
Amgen
Bristol-Myers Squibb
Genentech
Pfizer
AstraZeneca
MedImmune
Foundation Medicine
Addario Lung Cancer Foundation
Lung Cancer Alliance
LUNGevity Foundation
Free to Breathe
Lung Cancer Foundation of America
American Lung Association
American Cancer Society
Uniting Against Lung Cancer